Open AccessCoronavirus disease (COVID-19) and disseminated intravascular coagulation syndrome
Author(s) -
A. D. Makatsariya,
K. N. Grigoreva,
M. A. Mingalimov,
Victoria Bitsadze,
J. Kh. Khizroeva,
M. V. Tretyakova,
Ismaı̈l Elalamy,
A. S. Shkoda,
V. B. Nemirovskiy,
Д. В. Блинов,
D. V. Mitryuk
Publication year - 2020
Publication title -
akušerstvo, ginekologiâ i reprodukciâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.124
H-Index - 4
eISSN - 2500-3194
pISSN - 2313-7347
DOI - 10.17749/2313-7347.132
Subject(s) - medicine , disseminated intravascular coagulation , coagulopathy , fibrinogen , prothrombin time , covid-19 , intensive care medicine , d dimer , coronavirus , low molecular weight heparin , adverse effect , respiratory failure , intensive care , disease , heparin , infectious disease (medical specialty)
COVID-19 is an infectious disease caused by the beta-coronavirus SARS-CoV-2 that in 2020 has spread worldwide. In most severe patients, the clinical picture begins with respiratory failure further deteriorating up to multiple organ failure. Development of coagulopathy is the most adverse prognostic. Analyzing currently available clinical data revealed that 71.4 % and 0.6 % of survivors and fatal cases, respectively, demonstrated signs of overt disseminated intravascular coagulation (DIC). Monitoring D-dimer level, prothrombin time, platelet count and fibrinogen content is important for determining indications for treatment and hospitalization in COVID-19 patients. In case such parameters deteriorate, a more pro-active “aggressive” intensive care should be applied. Low molecular weight heparin (LMWH) should be administered to all patients with diagnosed COVID-19 infection (including non-critical patients) requiring hospitalization, but having no contraindications to LMWH.